NASDAQ$TEM
Tempus AI Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Tempus AI Inc reported strong revenue growth and improved profitability in Q4 2024.
Tempus AI Inc saw a 35.8% year-over-year revenue growth in Q4 2024, reaching $200.7 million. The company reported a net loss of $13.0 million, significantly improving from the prior year's loss. Adjusted EBITDA also improved, and gross profit increased by 49.7%, driven by the growth in Data and Services. The company also announced its acquisition of Ambry Genetics, which is expected to strengthen its market position.
- Q4 2024 revenue increased 35.8% YoY to $200.7 million.
- Genomics revenue reached $120.4 million, while Data and Services generated $80.2 million.
- Net loss improved to $13.0 million, compared to $50.5 million in Q4 2023.
- Adjusted EBITDA improved to -$7.8 million from -$35.1 million in Q4 2023.
Headline financials
Revenue & EPS history
Tempus AI Inc · Revenue · Quarterly
$201M
Revenue by segment
Tempus AI Inc · $146M total across 2 segments · Q1 2024
- Diagnostics$103M—70.3%
- Data and Applications$43.3M—29.7%
Forward guidance
Tempus AI expects FY 2025 revenue to reach $1.24 billion, with positive Adjusted EBITDA of $5 million.
Tailwinds
- Projected 79% revenue growth in FY 2025.
- Expected positive Adjusted EBITDA of $5 million.
- Strong market positioning with the acquisition of Ambry Genetics.
- Expansion of AI-based diagnostic solutions.
- New reimbursement approvals for Tempus ECG-AF algorithm.
Headwinds
- Ongoing net losses despite revenue growth.
- Stock-based compensation continues to impact profitability.
- Macroeconomic uncertainties may affect demand.
- Regulatory risks in AI-based healthcare solutions.
- Increased competition in the precision medicine industry.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q4 2024
-0.5%
Avg return
Earnings day
+10.9%
Avg return
5 days after
+12.9%
Avg return
30 days after
50%
5 / 10 earnings
Positive
+12.6%
Q1 2025
Best reaction
-15.0%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.1% | -10.7% | -7.2% | |
| Q4 2025 | +3.6% | -8.0% | -26.5% | |
| Q3 2025 | -2.7% | -15.0% | -9.3% | |
| Q2 2025 | +3.4% | +18.5% | +35.5% | |
| Q1 2025 | +12.6% | +20.1% | +18.9% | |
| Q4 2024 | -15.0% | -19.2% | -25.3% | |
| Q3 2024 | -3.4% | +60.2% | +25.9% | |
| Q3 2023 | -3.4% | +60.2% | +25.9% | |
| Q2 2024 | +1.6% | +1.4% | +45.6% | |
| Q2 2023 | +1.6% | +1.4% | +45.6% | |
| Q1 2024 | — | — | — | |
| Q1 2023 | — | — | — | |
| Q4 2022 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro